Sativex at High Fixed Doses Reduced Cannabis Withdrawal Symptoms in Dependent Users

Proof-of-concept, double-blind, placebo-controlled trial using an ABACADAE design (four smoking-as-usual conditions alternating with four abstinence conditions). Nine cannabis-dependent subjects received randomized, counterbalanced doses of Sativex or placebo during abstinence periods. Withdrawal, craving, and subjective effects were measured with validated instruments. Compliance was verified by self-reports, vial weight, and toxicology.

There is currently no approved pharmacological treatment for cannabis dependence. This study provides proof-of-concept that Sativex, at appropriately high doses, can manage withdrawal symptoms, which is often the primary barrier to successful cannabis cessation. The finding that self-titrated doses were insufficient is clinically important for treatment design.

Cannabis withdrawal is now recognized as a clinical syndrome, but no pharmacotherapy exists for it. Sativex offers a controlled-dose approach to agonist substitution therapy (similar to methadone for opioid dependence). The challenge is that patients naturally choose lower doses when self-titrating, which may be insufficient for symptom relief.

Very small sample size (9 participants). Proof-of-concept design does not establish efficacy. The alternating design with multiple conditions is complex. The dose of Sativex that worked was high and may raise concerns about simply substituting one cannabinoid product for another. Craving was not reduced, which could limit real-world effectiveness.